Fixed-Duration Ibrutinib Plus Obinutuzumab Followed by Measurable Residual Disease–Guided Immunochemotherapy in Patients With Previously Untreated CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A fixed-duration, immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
Blood Adv 2023 Apr 07;[EPub Ahead of Print], AS Michallet, R Letestu, M Le Garff-Tavernier, L Campos, M Ticchioni, MS Dilhuydy, S Morisset, V Rouille, B Mahe, K Laribi, B Villemagne, EF Ferrant, O Tournilhac, AJ Delmer, L Molina, V Leblond, C Tomowiak, S De Guibert, F Orsini Piocelle, A Banos, P Carassou, G Cartron, LM Fornecker, L Ysebaert, C Dartigeas, M Truchan-Graczyk, JP Vilque, T Aurran Schleinitz, F Cymbalista, S Leprêtre, V Lévy, F Nguyen-Khac, P FeugierFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.